Insulin icodec/semaglutide

Last updated

Insulin icodec/semaglutide
Combination of
Insulin icodec Insulin analog
Semaglutide GLP-1 receptor agonist
Clinical data
ATC code
  • None

Insulin icodec/semaglutide is an experimental fixed-dose combination of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk. [1] [2] [3] The combination contains insulin icodec, a basal insulin analog; and semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist. [4] Insulin icodec regulates glucose metabolism by binding to insulin receptors. [4] Semaglutide regulates insulin and glucagon secretion in a glucose-dependent manner by selectively binding to and activating the GLP-1 receptor, the target for native GLP-1. [4]

Contents

Society and culture

In September 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kyinsu, intended for treatment of type 2 diabetes mellitus. [4] The applicant for this medicinal product is Novo Nordisk A/S. [4]

References

  1. ↑ Kalra, Sanjay; Bhattacharya, Saptarshi; Kapoor, Nitin (August 2021). "Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)". Diabetes Therapy. 12 (8): 2133–2147. doi:10.1007/s13300-021-01113-y. ISSN   1869-6953. PMC   8342688 . PMID   34268675.
  2. ↑ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 5 November 2023.
  3. ↑ Doctorx (12 February 2020). "Novo Nordisk's Insulin Products, Pipeline May Energize The Stock". Seeking Alpha. Retrieved 5 November 2023.[ dead link ]
  4. 1 2 3 4 5 "Kyinsu EPAR". European Medicines Agency (EMA). 19 September 2025. Retrieved 27 September 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.